{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:51:40Z","timestamp":1782910300164,"version":"3.54.5"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>GV1001 is a peptide consisting of 16 amino acids derived from the catalytic subunit of human telomerase reverse transcriptase. A recent phase II clinical trial in patients with Alzheimer disease (AD) showed that GV1001 effectively improved memory impairment with proven safety, leading to larger clinical trials. However, the mechanisms underlying therapeutic effects of GV1001 on AD remain elusive. Here, we report that GV1001 reduces amyloid plaque burden and rescues synaptic loss and memory deficits in 5xFAD mice by increasing microglial migration toward large amyloid plaques and amyloid \u03b2 degradation. Single-cell RNA-sequencing revealed that GV1001 promoted the migratory and phagocytic phenotypes by modulating disease-associated microglial profiles. At the molecular level, through virtual target screening and docking simulation combined with peptide pulldown, we identified that bradykinin receptor 1 is the binding target of GV1001. Furthermore, we revealed that GV1001 facilitated microglial migration and amyloid \u03b2 phagocytosis in an mTORC2-dependent manner. Collectively, our work demonstrates the amyloidolytic effects and the relevant in-depth signaling mechanism of GV1001 in microglia, suggesting GV1001 as a promising disease-modifying therapeutic agent for AD.<\/jats:p>","DOI":"10.1038\/s12276-026-01729-9","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:15:09Z","timestamp":1780470909000},"page":"1789-1805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease"],"prefix":"10.1038","volume":"58","author":[{"given":"Younghwan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeri","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeo Jin","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eum Ji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehee","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6233-1583","authenticated-orcid":false,"given":"Ja Wook","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6096-2231","authenticated-orcid":false,"given":"Taekwon","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangjae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Woon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"1729_CR1","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1126\/science.1228541","volume":"337","author":"DJ Selkoe","year":"2012","unstructured":"Selkoe, D. J. Preventing Alzheimer\u2019s disease. Science 337, 1488\u20131492 (2012).","journal-title":"Science"},{"key":"1729_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran, E. & De Strooper, B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov 21, 306\u2013318 (2022).","journal-title":"Nat Rev Drug Discov"},{"key":"1729_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner, F. L. et al. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16, 358\u2013372 (2015).","journal-title":"Nat Rev Neurosci"},{"key":"1729_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-018-0523-8","volume":"10","author":"KE Tansey","year":"2018","unstructured":"Tansey, K. E. et al. Genetic risk for Alzheimer\u2019s disease is concentrated in specific macrophage and microglial transcriptional networks. Genome Med 10, 1\u201310 (2018).","journal-title":"Genome Med"},{"key":"1729_CR5","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41467-021-21823-y","volume":"12","author":"G Novikova","year":"2021","unstructured":"Novikova, G. et al. Integration of Alzheimer\u2019s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat Commun 12, 1610 (2021).","journal-title":"Nat Commun"},{"key":"1729_CR6","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41588-021-00921-z","volume":"53","author":"DP Wightman","year":"2021","unstructured":"Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer\u2019s disease. Nat Genet 53, 1276\u20131282 (2021).","journal-title":"Nat Genet"},{"key":"1729_CR7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41590-018-0212-1","volume":"19","author":"WM Song","year":"2018","unstructured":"Song, W. M. & Colonna, M. The identity and function of microglia in neurodegeneration. Nat Immunol 19, 1048\u20131058 (2018).","journal-title":"Nat Immunol"},{"key":"1729_CR8","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.1038\/ncomms7176","volume":"6","author":"C Condello","year":"2015","unstructured":"Condello, C. et al. Microglia constitute a barrier that prevents neurotoxic protofibrillar A\u03b242 hotspots around plaques. Nat Commun 6, 6176 (2015).","journal-title":"Nat Commun"},{"key":"1729_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/15548627.2018.1556946","volume":"15","author":"J-W Lee","year":"2019","unstructured":"Lee, J.-W. et al. TLR4 (Toll-like receptor 4) activation suppresses autophagy through inhibition of FOXO3 and impairs phagocytic capacity of microglia. Autophagy 15, 753\u2013770 (2019).","journal-title":"Autophagy"},{"key":"1729_CR10","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1038\/s41467-022-29653-2","volume":"13","author":"H Nam","year":"2022","unstructured":"Nam, H. et al. Presenilin 2 N141I mutation induces hyperactive immune response through the epigenetic repression of REV-ERB\u03b1. Nat Commun 13, 1972 (2022).","journal-title":"Nat Commun"},{"key":"1729_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cell.2017.07.023","volume":"170","author":"TK Ulland","year":"2017","unstructured":"Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in Alzheimer\u2019s disease. Cell 170, 649\u2013663.e13 (2017).","journal-title":"Cell"},{"key":"1729_CR12","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910606","volume":"12","author":"A Sierksma","year":"2020","unstructured":"Sierksma, A. et al. Novel Alzheimer risk genes determine the microglia response to amyloid-\u03b2 but not to TAU pathology. EMBO Mol Med 12, e10606 (2020).","journal-title":"EMBO Mol Med"},{"key":"1729_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.cell.2018.05.003","volume":"173","author":"A Deczkowska","year":"2018","unstructured":"Deczkowska, A. et al. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 173, 1073\u20131081 (2018).","journal-title":"Cell"},{"key":"1729_CR14","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169, 1276\u20131290.e17 (2017).","journal-title":"Cell"},{"key":"1729_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrd2081","volume":"5","author":"JW Shay","year":"2006","unstructured":"Shay, J. W. & Wright, W. E. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 5, 577\u2013584 (2006).","journal-title":"Nat Rev Drug Discov"},{"key":"1729_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-10-209","volume":"10","author":"TF Greten","year":"2010","unstructured":"Greten, T. F. et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 10, 1\u20137 (2010).","journal-title":"BMC Cancer"},{"key":"1729_CR17","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/sj.bjc.6603437","volume":"95","author":"S Bernhardt","year":"2006","unstructured":"Bernhardt, S. et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I\/II study. Br J Cancer 95, 1474\u20131482 (2006).","journal-title":"Br J Cancer"},{"key":"1729_CR18","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00262-006-0145-7","volume":"55","author":"PF Brunsvig","year":"2006","unstructured":"Brunsvig, P. F. et al. Telomerase peptide vaccination: a phase I\/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55, 1553\u20131564 (2006).","journal-title":"Cancer Immunol Immunother"},{"key":"1729_CR19","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1158\/1078-0432.CCR-11-0184","volume":"17","author":"JA Kyte","year":"2011","unstructured":"Kyte, J. A. et al. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients telomerase vaccine and temozolomide in stage IV melanoma. Clin Cancer Res 17, 4568\u20134580 (2011).","journal-title":"Clin Cancer Res"},{"key":"1729_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00803-w","volume":"13","author":"S-H Koh","year":"2021","unstructured":"Koh, S.-H. et al. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer\u2019s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res Ther 13, 1\u201311 (2021).","journal-title":"Alzheimers Res Ther"},{"key":"1729_CR21","doi-asserted-by":"crossref","unstructured":"Zdrazil, B. et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res gkad1004 52, D1180\u2013D1192 (2023).","DOI":"10.1093\/nar\/gkad1004"},{"key":"1729_CR22","doi-asserted-by":"publisher","first-page":"W612","DOI":"10.1093\/nar\/gkv352","volume":"43","author":"M Davies","year":"2015","unstructured":"Davies, M. et al. ChEMBL web services: streamlining access to drug discovery data and utilities. Nucleic Acids Res 43, W612\u2013W620 (2015).","journal-title":"Nucleic Acids Res"},{"key":"1729_CR23","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/bioinformatics\/btv302","volume":"31","author":"WK Chan","year":"2015","unstructured":"Chan, W. K. et al. GLASS: a comprehensive database for experimentally validated GPCR\u2013ligand associations. Bioinformatics 31, 3035\u20133042 (2015).","journal-title":"Bioinformatics"},{"key":"1729_CR24","doi-asserted-by":"publisher","first-page":"D395","DOI":"10.1093\/nar\/gkac1013","volume":"51","author":"G P\u00e1ndy-Szekeres","year":"2023","unstructured":"P\u00e1ndy-Szekeres, G. et al. GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources. Nucleic Acids Res 51, D395\u2013D402 (2023).","journal-title":"Nucleic Acids Res"},{"key":"1729_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ymeth.2015.07.004","volume":"93","author":"M Blaszczyk","year":"2016","unstructured":"Blaszczyk, M. et al. Modeling of protein\u2013peptide interactions using the CABS-dock web server for binding site search and flexible docking. Methods 93, 72\u201383 (2016).","journal-title":"Methods"},{"key":"1729_CR26","doi-asserted-by":"publisher","first-page":"W419","DOI":"10.1093\/nar\/gkv456","volume":"43","author":"M Kurcinski","year":"2015","unstructured":"Kurcinski, M. et al. CABS-dock web server for the flexible docking of peptides to proteins without prior knowledge of the binding site. Nucleic Acids Res 43, W419\u2013W424 (2015).","journal-title":"Nucleic Acids Res"},{"key":"1729_CR27","doi-asserted-by":"publisher","first-page":"W530","DOI":"10.1093\/nar\/gkab294","volume":"49","author":"MF Adasme","year":"2021","unstructured":"Adasme, M. F. et al. PLIP 2021: expanding the scope of the protein\u2013ligand interaction profiler to DNA and RNA. Nucleic Acids Res 49, W530\u2013W534 (2021).","journal-title":"Nucleic Acids Res"},{"key":"1729_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbi.2023.10.021","volume":"115","author":"H Park","year":"2024","unstructured":"Park, H. et al. GV1001 modulates neuroinflammation and improves memory and behavior through the activation of gonadotropin-releasing hormone receptors in a triple transgenic Alzheimer\u2019s disease mouse model. Brain Behav Immun 115, 295\u2013307 (2024).","journal-title":"Brain Behav Immun"},{"key":"1729_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bbrc.2020.02.074","volume":"525","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Disrupted blood\u2013brain barrier in 5\u00d7 FAD mouse model of Alzheimer\u2019s disease can be mimicked and repaired in vitro with neural stem cell-derived exosomes. Biochem Biophys Res Commun 525, 192\u2013196 (2020).","journal-title":"Biochem Biophys Res Commun"},{"key":"1729_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.713726","volume":"13","author":"AL Oblak","year":"2021","unstructured":"Oblak, A. L. et al. Comprehensive evaluation of the 5XFAD mouse model for preclinical testing applications: a MODEL-AD study. Front Aging Neurosci 13, 713726 (2021).","journal-title":"Front Aging Neurosci"},{"key":"1729_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09118-9","volume":"10","author":"L Zhong","year":"2019","unstructured":"Zhong, L. et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer\u2019s disease model. Nat Commun 10, 1365 (2019).","journal-title":"Nat Commun"},{"key":"1729_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-6606-4-3","volume":"4","author":"Y-w Zhang","year":"2011","unstructured":"Zhang, Y. -w et al. APP processing in Alzheimer\u2019s disease. Mol Brain 4, 1\u201313 (2011).","journal-title":"Mol Brain"},{"key":"1729_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.835824","volume":"9","author":"M Vailati-Riboni","year":"2022","unstructured":"Vailati-Riboni, M. et al. Dietary fiber as a counterbalance to age-related microglial cell dysfunction. Front Nutr 9, 835824 (2022).","journal-title":"Front Nutr"},{"key":"1729_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s40478-022-01450-4","volume":"10","author":"JA Slota","year":"2022","unstructured":"Slota, J. A. et al. Dysregulation of neuroprotective astrocytes, a spectrum of microglial activation states, and altered hippocampal neurogenesis are revealed by single-cell RNA sequencing in prion disease. Acta Neuropathol Commun 10, 161 (2022).","journal-title":"Acta Neuropathol Commun"},{"key":"1729_CR35","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41593-023-01355-y","volume":"26","author":"Z Yin","year":"2023","unstructured":"Yin, Z. et al. Identification of a protective microglial state mediated by miR-155 and interferon-\u03b3 signaling in a mouse model of Alzheimer\u2019s disease. Nat Neurosci 26, 1196\u20131207 (2023).","journal-title":"Nat Neurosci"},{"key":"1729_CR36","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41590-023-01627-6","volume":"24","author":"Z Yin","year":"2023","unstructured":"Yin, Z. et al. APOE4 impairs the microglial response in Alzheimer\u2019s disease by inducing TGFbeta-mediated checkpoints. Nat Immunol 24, 1839\u20131853 (2023).","journal-title":"Nat Immunol"},{"key":"1729_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1308972","volume":"17","author":"Y Morisaki","year":"2023","unstructured":"Morisaki, Y. et al. LAG-3 expression in microglia regulated by IFN-gamma\/STAT1 pathway and metalloproteases. Front Cell Neurosci 17, 1308972 (2023).","journal-title":"Front Cell Neurosci"},{"key":"1729_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk3690","volume":"17","author":"W Brandao","year":"2025","unstructured":"Brandao, W. et al. Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy. Sci Transl Med 17, eadk3690 (2025).","journal-title":"Sci Transl Med"},{"key":"1729_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-018-1250-1","volume":"15","author":"Y Fang","year":"2018","unstructured":"Fang, Y. et al. The adhesion and migration of microglia to \u03b2-amyloid (A\u03b2) is decreased with aging and inhibited by Nogo\/NgR pathway. J Neuroinflamm 15, 1\u201316 (2018).","journal-title":"J Neuroinflamm"},{"key":"1729_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau6328","volume":"5","author":"R-Y Pan","year":"2019","unstructured":"Pan, R.-Y. et al. Sodium rutin ameliorates Alzheimer\u2019s disease-like pathology by enhancing microglial amyloid-\u03b2 clearance. Sci Adv 5, eaau6328 (2019).","journal-title":"Sci Adv"},{"key":"1729_CR41","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann, S. et al. The TREM2\u2013APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566\u2013581.e9 (2017).","journal-title":"Immunity"},{"key":"1729_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cell.2006.12.039","volume":"128","author":"G Giannone","year":"2007","unstructured":"Giannone, G. et al. Lamellipodial actin mechanically links myosin activity with adhesion-site formation. Cell 128, 561\u2013575 (2007).","journal-title":"Cell"},{"key":"1729_CR43","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.cell.2011.06.010","volume":"145","author":"A Ridley","year":"2011","unstructured":"Ridley, A. Life at the leading edge. Cell 145, 1012\u20131022 (2011).","journal-title":"Cell"},{"key":"1729_CR44","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1523\/JNEUROSCI.4814-07.2008","volume":"28","author":"T Bolmont","year":"2008","unstructured":"Bolmont, T. et al. Dynamics of the microglial\/amyloid interaction indicate a role in plaque maintenance. J Neurosci 28, 4283\u20134292 (2008).","journal-title":"J Neurosci"},{"key":"1729_CR45","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/ijms23020811","volume":"23","author":"ME Bragina","year":"2022","unstructured":"Bragina, M. E. et al. The SwissSimilarity 2021 web tool: novel chemical libraries and additional methods for an enhanced ligand-based virtual screening experience. Int J Mol Sci 23, 811 (2022).","journal-title":"Int J Mol Sci"},{"key":"1729_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pneurobio.2018.01.003","volume":"165","author":"A Nokkari","year":"2018","unstructured":"Nokkari, A. et al. Implication of the kallikrein-kinin system in neurological disorders: quest for potential biomarkers and mechanisms. Prog Neurobiol 165, 26\u201350 (2018).","journal-title":"Prog Neurobiol"},{"key":"1729_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.peptides.2018.05.007","volume":"105","author":"F Marceau","year":"2018","unstructured":"Marceau, F. et al. Bifunctional ligands of the bradykinin B2 and B1 receptors: an exercise in peptide hormone plasticity. Peptides 105, 37\u201350 (2018).","journal-title":"Peptides"},{"key":"1729_CR48","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/288705a0","volume":"288","author":"K Arakawa","year":"1980","unstructured":"Arakawa, K. & Maruta, H. Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed kinin\u2013tensin enzyme system. Nature 288, 705\u2013706 (1980).","journal-title":"Nature"},{"key":"1729_CR49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fendo.2017.00082","volume":"8","author":"K Asraf","year":"2017","unstructured":"Asraf, K. et al. Involvement of the bradykinin B1 receptor in microglial activation: in vitro and in vivo studies. Front Endocrinol 8, 82 (2017).","journal-title":"Front Endocrinol"},{"key":"1729_CR50","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1515\/hsz-2015-0219","volume":"397","author":"K Asraf","year":"2016","unstructured":"Asraf, K. et al. Differential effect of intranasally administrated kinin B1 and B2 receptor antagonists in Alzheimer\u2019s disease mice. Biol Chem 397, 345\u2013351 (2016).","journal-title":"Biol Chem"},{"key":"1729_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-7-61","volume":"7","author":"S Fleisher-Berkovich","year":"2010","unstructured":"Fleisher-Berkovich, S. et al. Distinct modulation of microglial amyloid \u03b2 phagocytosis and migration by neuropeptides. J Neuroinflamm 7, 1\u201313 (2010).","journal-title":"J Neuroinflamm"},{"key":"1729_CR52","doi-asserted-by":"publisher","first-page":"13065","DOI":"10.1523\/JNEUROSCI.3467-07.2007","volume":"27","author":"M Ifuku","year":"2007","unstructured":"Ifuku, M. et al. Bradykinin-induced microglial migration mediated by B1-bradykinin receptors depends on Ca2+ influx via reverse-mode activity of the Na+\/Ca2+ exchanger. J Neurosci 27, 13065\u201313073 (2007).","journal-title":"J Neurosci"},{"key":"1729_CR53","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12079-021-00652-0","volume":"16","author":"D Rex","year":"2022","unstructured":"Rex, D. et al. A modular map of bradykinin-mediated inflammatory signaling network. J Cell Commun Signal 16, 301\u2013310 (2022).","journal-title":"J Cell Commun Signal"},{"key":"1729_CR54","doi-asserted-by":"crossref","unstructured":"Senoo, H. et al. Hetero-oligomerization of Rho and Ras GTPases connects GPCR activation to mTORC2-AKT signaling. Cell Rep 33, 108427 (2020).","DOI":"10.1016\/j.celrep.2020.108427"},{"key":"1729_CR55","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/jcp.24668","volume":"229","author":"S Srivastava","year":"2014","unstructured":"Srivastava, S. et al. Bradykinin regulates osteoblast differentiation by Akt\/ERK\/NF\u03baB signaling axis. J Cell Physiol 229, 2088\u20132105 (2014).","journal-title":"J Cell Physiol"},{"key":"1729_CR56","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274\u2013293 (2012).","journal-title":"Cell"},{"key":"1729_CR57","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger, S. et al. TOR signaling in growth and metabolism. Cell 124, 471\u2013484 (2006).","journal-title":"Cell"},{"key":"1729_CR58","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960\u2013976 (2017).","journal-title":"Cell"},{"key":"1729_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33872-y","volume":"13","author":"N Chantaravisoot","year":"2023","unstructured":"Chantaravisoot, N. et al. mTORC2 interactome and localization determine aggressiveness of high-grade glioma cells through association with gelsolin. Sci Rep 13, 7037 (2023).","journal-title":"Sci Rep"},{"key":"1729_CR60","doi-asserted-by":"publisher","first-page":"14963","DOI":"10.1074\/jbc.M114.627794","volume":"290","author":"D Rispal","year":"2015","unstructured":"Rispal, D. et al. Target of rapamycin complex 2 regulates actin polarization and endocytosis via multiple pathways. J Biol Chem 290, 14963\u201314978 (2015).","journal-title":"J Biol Chem"},{"key":"1729_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep15193","volume":"5","author":"JL Johnson","year":"2015","unstructured":"Johnson, J. L. et al. TORC2: a novel target for treating age-associated memory impairment. Sci Rep 5, 1\u20139 (2015).","journal-title":"Sci Rep"},{"key":"1729_CR62","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri3901","volume":"15","author":"T Weichhart","year":"2015","unstructured":"Weichhart, T. et al. Regulation of innate immune cell function by mTOR. Nat Rev Immunol 15, 599\u2013614 (2015).","journal-title":"Nat Rev Immunol"},{"key":"1729_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.500","volume":"7","author":"A Fleming","year":"2011","unstructured":"Fleming, A. et al. Chemical modulators of autophagy as biological probes and potential therapeutics. Nat Chem Biol 7, 9\u201317 (2011).","journal-title":"Nat Chem Biol"},{"key":"1729_CR64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","volume":"127","author":"E Jacinto","year":"2006","unstructured":"Jacinto, E. et al. SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125\u2013137 (2006).","journal-title":"Cell"},{"key":"1729_CR65","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"D-H Kim","year":"2002","unstructured":"Kim, D.-H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163\u2013175 (2002).","journal-title":"Cell"},{"key":"1729_CR66","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fimmu.2020.00430","volume":"11","author":"A Benmamar-Badel","year":"2020","unstructured":"Benmamar-Badel, A. et al. Protective microglial subset in development, aging, and disease: lessons from transcriptomic studies. Front Immunol 11, 430 (2020).","journal-title":"Front Immunol"},{"key":"1729_CR67","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1016\/j.cell.2022.09.030","volume":"185","author":"H Ennerfelt","year":"2022","unstructured":"Ennerfelt, H. et al. SYK coordinates neuroprotective microglial responses in neurodegenerative disease. Cell 185, 4135\u20134152.e22 (2022).","journal-title":"Cell"},{"key":"1729_CR68","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1001\/jama.2021.3854","volume":"325","author":"GC Alexander","year":"2021","unstructured":"Alexander, G. C. et al. Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA 325, 1717\u20131718 (2021).","journal-title":"JAMA"},{"key":"1729_CR69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. New Engl J Med 388, 9\u201321 (2023).","journal-title":"New Engl J Med"},{"key":"1729_CR70","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"1729_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43933-5","volume":"14","author":"E Solopova","year":"2023","unstructured":"Solopova, E. et al. Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease. Nat Commun 14, 8220 (2023).","journal-title":"Nat Commun"},{"key":"1729_CR72","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/d41586-023-01537-5","volume":"617","author":"S Reardon","year":"2023","unstructured":"Reardon, S. Alzheimer\u2019s drug donanemab: what promising trial means for treatments. Nature 617, 232\u2013233 (2023).","journal-title":"Nature"},{"key":"1729_CR73","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fnmol.2019.00234","volume":"12","author":"B Ji","year":"2019","unstructured":"Ji, B. et al. The dual role of kinin\/kinin receptors system in Alzheimer\u2019s disease. Front Mol Neurosci 12, 234 (2019).","journal-title":"Front Mol Neurosci"},{"key":"1729_CR74","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.neuroscience.2007.11.009","volume":"151","author":"R Prediger","year":"2008","unstructured":"Prediger, R. et al. Genetic deletion or antagonism of kinin B1 and B2 receptors improves cognitive deficits in a mouse model of Alzheimer\u2019s disease. Neuroscience 151, 631\u2013643 (2008).","journal-title":"Neuroscience"},{"key":"1729_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-10-57","volume":"10","author":"B Lacoste","year":"2013","unstructured":"Lacoste, B. et al. Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer\u2019s disease mice. J Neuroinflamm 10, 1\u201318 (2013).","journal-title":"J Neuroinflamm"},{"key":"1729_CR76","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1515\/BC.2006.022","volume":"387","author":"M Noda","year":"2006","unstructured":"Noda, M. et al. Anti-inflammatory effects of kinins via microglia in the central nervous system. Biol Chem 387, 167\u2013171 (2006).","journal-title":"Biol Chem"},{"key":"1729_CR77","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neuint.2007.06.017","volume":"51","author":"M Noda","year":"2007","unstructured":"Noda, M. et al. Multifunctional effects of bradykinin on glial cells in relation to potential anti-inflammatory effects. Neurochem Int 51, 185\u2013191 (2007).","journal-title":"Neurochem Int"},{"key":"1729_CR78","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ajpath.2013.01.021","volume":"182","author":"GF Passos","year":"2013","unstructured":"Passos, G. F. et al. The bradykinin B1 receptor regulates A\u03b2 deposition and neuroinflammation in Tg-SwDI mice. Am J Pathol 182, 1740\u20131749 (2013).","journal-title":"Am J Pathol"},{"key":"1729_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104833","volume":"139","author":"PK Singh","year":"2020","unstructured":"Singh, P. K. et al. Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer\u2019s patients. Neurobiol Dis 139, 104833 (2020).","journal-title":"Neurobiol Dis"},{"key":"1729_CR80","doi-asserted-by":"crossref","unstructured":"Srinivasan, K. et al. Alzheimer\u2019s patient microglia exhibit enhanced aging and unique transcriptional activation. Cell Rep 31, 107843 (2020)","DOI":"10.1016\/j.celrep.2020.107843"},{"key":"1729_CR81","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1124\/jpet.103.059527","volume":"309","author":"J Gougat","year":"2004","unstructured":"Gougat, J. et al. SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 309, 661\u2013669 (2004).","journal-title":"J Pharmacol Exp Ther"},{"key":"1729_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-6-11","volume":"6","author":"S Talbot","year":"2009","unstructured":"Talbot, S. et al. Cellular localization of kinin B1 receptor in the spinal cord of streptozotocin-diabetic rats with a fluorescent [Nalpha-Bodipy]-des-Arg9-bradykinin. J Neuroinflamm 6, 11 (2009).","journal-title":"J Neuroinflamm"},{"key":"1729_CR83","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/syn.20196","volume":"58","author":"MM Campos","year":"2005","unstructured":"Campos, M. M. et al. Autoradiographic distribution and alterations of kinin B(2) receptors in the brain and spinal cord of streptozotocin-diabetic rats. Synapse 58, 184\u2013192 (2005).","journal-title":"Synapse"},{"key":"1729_CR84","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neuro.2016.05.022","volume":"55","author":"H-H Park","year":"2016","unstructured":"Park, H.-H. et al. Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals. Neurotoxicology 55, 131\u2013141 (2016).","journal-title":"Neurotoxicology"},{"key":"1729_CR85","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.neurobiolaging.2013.12.015","volume":"35","author":"H-H Park","year":"2014","unstructured":"Park, H.-H. et al. The novel vaccine peptide GV1001 effectively blocks \u03b2-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiol Aging 35, 1255\u20131274 (2014).","journal-title":"Neurobiol Aging"},{"key":"1729_CR86","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/S0140-6736(17)32399-1","volume":"390","author":"RM Anderson","year":"2017","unstructured":"Anderson, R. M. et al. Why do so many clinical trials of therapies for Alzheimer\u2019s disease fail? Lancet 390, 2327\u20132329 (2017).","journal-title":"Lancet"},{"key":"1729_CR87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(18)31896-8","volume":"393","author":"JM Schott","year":"2019","unstructured":"Schott, J. M. et al. Unsuccessful trials of therapies for Alzheimer\u2019s disease. Lancet 393, 29 (2019).","journal-title":"Lancet"},{"key":"1729_CR88","first-page":"15","volume":"1","author":"S Kumari","year":"2023","unstructured":"Kumari, S. et al. Apoptosis in Alzheimer\u2019s disease: insight into the signaling pathways and therapeutic avenues. Apoptosis 1, 15 (2023).","journal-title":"Apoptosis"},{"key":"1729_CR89","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.cmet.2013.11.005","volume":"18","author":"E Motori","year":"2013","unstructured":"Motori, E. et al. Inflammation-induced alteration of astrocyte mitochondrial dynamics requires autophagy for mitochondrial network maintenance. Cell Metab 18, 844\u2013859 (2013).","journal-title":"Cell Metab"},{"key":"1729_CR90","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk9884","volume":"10","author":"F Yang","year":"2024","unstructured":"Yang, F. et al. Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection. Sci Adv 10, eadk9884 (2024).","journal-title":"Sci Adv"},{"key":"1729_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2022.100276","volume":"2","author":"W Agnew-Svoboda","year":"2022","unstructured":"Agnew-Svoboda, W. et al. A genetic tool for the longitudinal study of a subset of post-inflammatory reactive astrocytes. Cell Rep Methods 2, 100276 (2022).","journal-title":"Cell Rep Methods"},{"key":"1729_CR92","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1038\/s41591-023-02644-6","volume":"29","author":"S Sirko","year":"2023","unstructured":"Sirko, S. et al. Injury-specific factors in the cerebrospinal fluid regulate astrocyte plasticity in the human brain. Nat Med 29, 3149\u20133161 (2023).","journal-title":"Nat Med"},{"key":"1729_CR93","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01729-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01729-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01729-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:26:40Z","timestamp":1782908800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01729-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":93,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1729"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01729-9","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K. is an employer of GemVax & Kael Co., Ltd and holds equity in the company. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}